Is neoadjuvant treatment indicated in triple negative cT1N0 breast cancer?

Abstract

Triple negative breast cancer (TNBC) is the most aggressive subtype, including early BC. Neoadjuvant chemotherapy (NAC) has shown benefit in achieving more conservative surgeries, but also it is useful to determine therapeutic sensitivity, prognostic estimation, and consequent choice of an individualized adjuvant treatment. Traditionally, NAC was indicated in patients with cT2 (2 cm or more) TNBC. However, recent guidelines consider neoadjuvant treatment for cT1 TNBC patients. In this paper, we review the current evidence on neoadjuvant treatment in cT1 TNBC patients, including available signals on efficacy, choice of optimal regimen and identification of patients with the greatest potential benefit.